Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 63 entries
View as:

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Phase: N/A Priority: Normal
NCT ID: NCT01874522 Org: User:
Start: 07/31/13 End: 11/30/15 Due: 11/30/16

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04982926 Org: User:
Start: 09/16/21 End: 06/30/25 Due: 06/30/26

A Trial of TAS-114 in Combination With S-1

Phase: N/A Priority: Normal
NCT ID: NCT02454062 Org: User:
Start: 03/31/13 End: 09/30/17 Due: 09/30/18

A Study of TAS-116 in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02965885 Org: User:
Start: 07/10/17 End: 05/03/19 Due: 05/03/20

An Investigation of TAS-119 Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02448589 Org: User:
Start: 09/30/14 End: 08/31/19 Due: 08/31/20

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00667628 Org: User:
Start: 04/24/08 End: 12/22/09 Due: 12/22/10

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Phase: N/A Priority: Normal
NCT ID: NCT01607957 Org: User:
Start: 06/17/12 End: 05/23/16 Due: 05/23/17

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01867879 Org: User:
Start: 06/30/13 End: 04/30/15 Due: 04/30/16

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Phase: N/A Priority: Normal
NCT ID: NCT05727176 Org: User:
Start: 07/05/23 End: 12/31/26 Due: 12/31/27

A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00756782 Org: User:
Start: 10/31/08 End: 12/31/08 Due: 12/31/09

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT02301117 Org: User:
Start: 01/31/15 End: 06/19/19 Due: 06/19/20

A Study of TAS-120 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02052778 Org: User:
Start: 07/21/14 End: 10/22/24 Due: 10/22/25

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Phase: N/A Priority: Normal
NCT ID: NCT05967689 Org: User:
Start: 07/31/23 End: 08/31/26 Due: 08/31/27

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05945823 Org: User:
Start: 07/13/23 End: 01/31/27 Due: 01/31/28

The CHOICE Registry

Phase: N/A Priority: Normal
NCT ID: NCT03148093 Org: User:
Start: 06/30/17 End: 12/13/17 Due: 12/13/18

A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Phase: N/A Priority: Normal
NCT ID: NCT03410927 Org: User:
Start: 04/06/18 End: 06/09/22 Due: 06/09/23

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04024436 Org: User:
Start: 01/28/20 End: 10/30/24 Due: 10/30/25

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Phase: N/A Priority: Normal
NCT ID: NCT03502668 Org: User:
Start: 07/27/18 End: 12/31/25 Due: 12/31/26

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase: N/A Priority: Normal
NCT ID: NCT05403450 Org: User:
Start: 06/23/22 End: 12/01/26 Due: 12/01/27

A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02025803 Org: User:
Start: 11/30/12 End: 07/07/17 Due: 07/07/18

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02286492 Org: User:
Start: - End: - Due: -

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Phase: N/A Priority: Normal
NCT ID: NCT01867866 Org: User:
Start: 05/31/13 End: 06/30/16 Due: 06/30/17

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02134067 Org: User:
Start: 08/31/14 End: 07/31/18 Due: 07/31/19

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01904253 Org: User:
Start: 07/31/13 End: 06/30/14 Due: 06/30/15

Evaluating Patients With Varying Degrees of Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT00398307 Org: User:
Start: 02/28/06 End: 09/30/10 Due: 09/30/11